| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CONCISE REPORT |
1 Department of Paediatric Rheumatology, Hospital for Children and Adolescents, University of Helsinki, 00290 Helsinki, Finland
2 Department of Paediatrics, University of Oulu, 90029 Oulu, Finland
3 Department of Paediatric Rheumatology, Rheumatism Foundation Hospital, 18120 Heinola, Finland
Correspondence to:
Correspondence to:
Dr P Lahdenne;
pekka.lahdenne{at}hus.fi
ABSTRACT
Objective: To study infliximab and etanercept in the treatment of refractory juvenile idiopathic arthritis (JIA).
Methods: In a non-randomised, prospective, open label study, 24 patients (mean age 10.2 years, range 3.3–16.3) with polyarticular JIA were treated with either infliximab (n=14) or etanercept (n=10). The patients had had active polyarthritis for at least one year and standard treatment had failed. Anti-tumour necrosis factor (TNF) treatment was added to the current drug treatment. Infliximab (3–4 mg/kg) was given intravenously at weeks 0, 2, and 6, and thereafter at 4 to 8 week intervals. Etanercept (0.4 mg/kg) was given subcutaneously twice a week. Improvement of the patients was assessed at 3, 6, and 12 months according to established JIA response criteria.
Results: In intention to treat analyses, patients in both treatment groups improved significantly. ACR Paediatric 50 was achieved at 3, 6, and 12 months by 9/10 (90%), 8/9 (89%), and 8/9 (89%) patients with etanercept and by 8/12 (67%), 10/12 (83%), and 7/9 (78%) with infliximab, respectively. At 12 months, ACR Paediatric 75 was achieved by 67% of patients in both treatment groups. Five withdrawals due to adverse effects or lack of efficacy occurred in the infliximab group and one due to lack of compliance in the etanercept group.
Conclusion: In this open label clinical study of active JIA, both infliximab and etanercept provided a significant rapid and sustained reduction in disease activity. Adequately powered randomised controlled trials are needed to elucidate the long term safety and efficacy of TNF modulators in the treatment of JIA.
Keywords: juvenile arthritis; tumour necrosis factor 
; etanercept; infliximab
Abbreviations: CHAQ, Children’s Health Assessment Questionnaire; CyA, cyclosporin A; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HQ, hydroxychloroquine; JIA, juvenile idiopathic arthritis; MTX, methotrexate; PRED, prednisolone; SSZ, sulfasalazine; TNF, tumour necrosis factor
This article has been cited by other articles:
|
|
 |
|
  V Gerloni, I Pontikaki, M Gattinara, and F Fantini Focus on adverse events of tumour necrosis factor {alpha} blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients Ann Rheum Dis, August 1, 2008; 67(8): 1145 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. A. Roord, W. de Jager, L. Boon, N. Wulffraat, A. Martens, B. Prakken, and F. van Wijk Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+Foxp3+ regulatory T cells Blood, May 15, 2008; 111(10): 5233 - 5241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Tynjala, K. Kotaniemi, P. Lindahl, K. Latva, K. Aalto, V. Honkanen, and P. Lahdenne Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis Rheumatology, March 1, 2008; 47(3): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kuek, B. L. Hazleman, J. H. Gaston, and A. J. K. Ostor Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab Rheumatology, November 1, 2006; 45(11): 1448 - 1449. [Full Text] [PDF]
|
|
|
|
 |
|
 L. J McCann, L. R Wedderburn, and N. Hasson JUVENILE IDIOPATHIC ARTHRITIS Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep29 - ep36. [Full Text] [PDF]
|
|
|
|
|
|
P Tynjala, P Lahdenne, P Vahasalo, H Kautiainen, and V Honkanen Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis Ann Rheum Dis, August 1, 2006; 65(8): 1044 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Laas, R Peltomaa, H Kautiainen, K Puolakka, and M Leirisalo-Repo Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment Ann Rheum Dis, July 1, 2006; 65(7): 924 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hashkes and R. M. Laxer Medical Treatment of Juvenile Idiopathic Arthritis JAMA, October 5, 2005; 294(13): 1671 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Horneff, H Schmeling, T Biedermann, I Foeldvari, G Ganser, H J Girschick, T Hospach, H I Huppertz, R Keitzer, R M Kuster, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis Ann Rheum Dis, December 1, 2004; 63(12): 1638 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tutar, F. Ekici, N. Nacar, S. Arici, and S. Atalay Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis Rheumatology, May 1, 2004; 43(5): 674 - 675. [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. GROUNDS and J. TORRISI Anti-TNF{alpha} (Remicade(R)) therapy protects dystrophic skeletal muscle from necrosis FASEB J, April 1, 2004; 18(6): 676 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Lucina Arch. Dis. Child., May 1, 2003; 88(5): 462 - 462. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
